Bruker Daltonics Appoints Hans Baum as Vice President of European Operations.To download high-resolution, print-ready JPEG JPEG in full Joint Photographic Experts Group Standard computer file format for storing graphic images in a compressed form for general use. JPEG images are compressed using a mathematical algorithm. images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption Business Editors Homeland Security Summit 2004 MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4651725 BILLERICA, Mass.--(BUSINESS WIRE)--June 1, 2004 Bruker Daltonics Inc., an operating company operating company A business that engages in transactions with outsiders. of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ), announces that Mr. Hans Baum has been appointed Vice President of European Operations. Mr. Baum will be responsible for the management of Bruker Daltonics' European operations, including sales, distribution and service, as well as European based manufacturing. After serving in the German Bundeswehr as NBC NBC in full National Broadcasting Co. Major U.S. commercial broadcasting company. It was formed in 1926 by RCA Corp., General Electric Co. (GE), and Westinghouse and was the first U.S. company to operate a broadcast network. defense officer, Mr. Baum started his business career with Bruker Daltonik GmbH in Germany in 1987, and in 1988 he became the MM1 Product Manager. In 1990, Mr. Baum was promoted to Sales Manager with responsibility for sales and applications in Germany for life-science systems and NBC detection systems. In 1997, he joined the Bruker Daltonik GmbH board of management, and in 1999 he became a Managing Director. Frank Laukien, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bruker Daltonics, stated: "We are very pleased to have Hans Baum in this position where he will address the opportunities of our European operations for further growth, increased efficiency and improved productivity, as well as accelerating profitability. Hans will drive our European operations to serve our diverse customers' needs and to expand the market for our innovative products." "I look forward to leading our European operations to serve our fast-growing markets even better," commented Hans Baum. "Our goal is to support innovative customer applications by supplying them with high-performance instruments and bioinformatics, backed up by reliable services and consumables. We will direct our European service and support teams to address the needs of our customers in the growing life-science mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. community with timely and high-quality services. Our long experience with NATO's NBC defense community also makes Bruker Daltonics a premier supplier of advanced chemical and biological detection systems for European homeland security and defense requirements." ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4651725 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion